SLCO1B1 Gene Variations among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine

OMICS A Journal of Integrative Biology

Volumn 20, Issue 9, 2016, Pages 538-545

  Aklillu, Eleni ^a   Habtewold, Abiy ^a,b   Ngaimisi, Eliford ^a,c   Yimer, Getnet ^a,b   Mugusi, Sabina ^c   Amogne, Wondwossen ^b   Reuter, Tasmin ^d   Meid, Andreas ^d   Hoffmann, Michael Marcus ^e   Weiss, Johanna ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

AFRICA SOUTH OF THE SAHARA; ARTICLE; ETHIOPIAN; EUROPEAN; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HAPLOTYPE; HUMAN; HYBRIDIZATION; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIAN; ALLELE; BLACK PERSON; CAUCASIAN; GENETICS; PHARMACOGENETICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; PRECISION MEDICINE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1;

EID: 84987864213     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2016.0119     Document Type: Article

References (38)

1. Aklillu E, Mugusi S, Ngaimisi E, et al. (2011). Frequency of the SLCO1B1 388A > G and the 521T > C polymorphism in Tanzania genotyped by a new LightCycler (R)-based method. Eur J Clin Pharmacol 67, 1139-1145.
2. Baciewicz AM, Chrisman CR, Finch CK, and Self TH. (2013). Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29, 1-12.
3. Cavalli-Sforza LLMP, and Piazza A. (1994). The History and Geography of Human Genes. New Jersey: Princeton University press, 535 p.
4. Chigutsa E, Visser ME, Swart EC, et al. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 55, 4122-4127.
5. Gengiah TN, Botha JH, Soowamber D, Naidoo K, and Abdool Karim SS. (2014). Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries 8, 987-993.
6. Hatta FH, and Aklillu E. (2015). P450 (Cytochrome) oxidoreductase gene (POR) common variant (POR28) significantly alters CYP2C9 activity in Swedish, But Not in Korean Healthy Subjects. OMICS 19, 777-781.
7. Hatta FH, Lundblad M, Ramsjo M, et al. (2015). Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex. OMICS 19, 346-353.
8. Holmes C, McDonald F, Jones M, and Graham J. (2016). Knowledge translation: Moving proteomics science to innovation in society. OMICS 20, 352-361.
9. International HapMap Consortium (2003). The international HapMap project. Nature 426, 789-796.
10. International HapMap Consortium (2005). A haplotype map of the human genome. Nature 437, 1299-1320.
11. International HapMap Consortium (2007a). A second generation human haplotype map of over 3. 1 million SNPs. Nature 449, 851-861.
12. International HapMap Consortium (2007b). Genome-wide detection and characterization of positive selection in human populations. Nature 449, 913-918.
13. International HapMap 3 Consortium (2010). Integrating common and rare genetic variation in diverse human populations. Nature 467, 52-58.
14. Jeremiah K, Denti P, Chigutsa E, et al. (2014). Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother 58, 3468-3474.
15. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B115+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15, 513-522.
16. Lin B, Strickland SJ, Wang J, et al. (2009). Meeting report: The 2009 Westlake International Conference on Personalized Medicine. OMICS 13, 285-289.
17. Lubomirov R, di Iulio J, Fayet A, et al.; Swiss HIV Cohort Study. (2010). ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 20, 217-230.
18. Mouly S, Lown KS, Kornhauser D, et al. (2002). Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72, 1-9.
19. Mwinyi J, Johne A, Bauer S, Roots I, and Gerloff T. (2004). Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75, 415-421.
20. Mwinyi J, Köpke K, Schaefer M, Roots I, and Gerloff T. (2008). Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol 64, 257-266.
21. Nakanishi T, and Tamai I. (2012). Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 27, 106-121.
22. Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan Africa populations. PLoS One 8, e67946.
23. Obaidat A, Roth M, and Hagenbuch B. (2012). The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52, 135-151.
24. Ohnhaus EE, Brockmeyer N, Dylewicz P, and Habicht H. (1987). The effect of antipyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther 42, 148-156.
25. Oshida K, Shimamura M, Seya K, Ando A, and Miyamoto Y. (2016). Identification of transporters involved in beraprost sodium transport in vitro. Eur J Drug Metab Pharmacokinet [Epub ahead of print]. DOI: 10. 1007/s13318-016-0327-4
26. Oshiro C, Mangravite L, Klein T, and Altman R. (2010). PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics 20, 211-216.
27. Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, and Simion A. (2016). Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet 55, 197-208.
28. Pagani L, Kivisild T, Tarekegn A, et al. (2012). Ethiopian genetic diversity reveals linguistic stratification and complex influences on the Ethiopian gene pool. Am J Hum Genet 91, 83-96.
29. Pasanen MK, Neuvonen M, Neuvonen PJ, and Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16, 873-879.
30. Paul GA, Gibbs JS, Boobis AR, Abbas A, and Wilkins MR. (2005). Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60, 107-112.
31. SEARCH Collaborative Group, Link E, Parish S, et al. (2008). SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 359, 789-799.
32. Sortica Vde A, Ojopi EB, Genro JP, et al. (2012). Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol 110, 460-468.
33. Treiber A, Schneiter R, Häusler S, and Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35, 1400-1407.
34. Weiner M, Egelund EF, Engle M, et al. (2014). Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 69, 1079-1085.
35. Weiner M, Peloquin C, Burman W, et al. (2010). Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 54, 4192-4200.
36. Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, and Kaneko S. (2003). Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol 23, 435-440.
37. Yimer G, Gry M, Amogne W, et al. (2014). Evaluation of patterns of liver toxicity in patients on antiretroviral and antituberculosis drugs: A prospective four arm observational study in Ethiopian patients. PLoS One 9, e94271.
38. Zhang Y, Han YH, Putluru SP, et al. (2016). Diclofenac and its acyl glucuronide: Determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Drug Metab Dispos 44, 320-328.